Schlegel, Jürgen (Prof. Dr.); Schmidt-Graf, Friederike (Priv.-Doz. Dr.)
Sprache:
en
Fachgebiet:
MED Medizin
Stichworte:
Glioblastoma multiforme, C6, ALDH, Ferroptosis
TU-Systematik:
MED 310; MED 600
Kurzfassung:
Glioblastoma multiforme (GBM) remains one of the deadliest tumor entities with average survival of 14,7 months and limited therapeutic options. Recent research has focused on cancer stem cells and identified ALDH isoenzymes as popular markers. In the popular C6 glioma model, Impact of ALDH1A3 on chemoresistance and its fit as a stem cell marker have never been investigated. Relevance of Ferroptosis, a regulated form of iron-dependent cell death, has never been investigated in the C6 glioma model.
«
Glioblastoma multiforme (GBM) remains one of the deadliest tumor entities with average survival of 14,7 months and limited therapeutic options. Recent research has focused on cancer stem cells and identified ALDH isoenzymes as popular markers. In the popular C6 glioma model, Impact of ALDH1A3 on chemoresistance and its fit as a stem cell marker have never been investigated. Relevance of Ferroptosis, a regulated form of iron-dependent cell death, has never been investigated in the C6 glioma model...
»
Übersetzte Kurzfassung:
Mit einem durchschnittlichen Überleben von 14,7 Monaten ist das Glioblastom (GBM) weiterhin eine der tödlichsten Tumorentitäten. In anderen Tumoren sind als brauchbare Biomarker von Tumorstammzellen ALDH Isoenzyme identifiziert worden. Die Rolle des Isoenzyms ALDH1A3, ebenso wie die Ferroptose als neue Form eines Eisen-abhängigen Zelltods, sind im im C6 in vitro Modell noch nie untersucht worden.